Back to mobile site

Amarin Corp Plc (AMRN) Post Smaller Q2 Loss on $5.5M in Revenue

August 8, 2013 4:05 PM EDT
Amarin Corp Plc (NASDAQ: AMRN) reported Q2 EPS of ($0.26), versus a loss of ($0.38) last year. Product revenue for the quarter came in at $5.5 million versus no revenue last year.

"Since the end of Q1, revenues, prescription levels, prescribing physicians and lives covered under Tier 2 have all more than doubled," said Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "We have witnessed the awareness, knowledge level and utilization of Vascepa strengthen and expand across our group of targeted physicians. The efficacy and safety profile of Vascepa for its approved indication continue to be well received and we plan to continue to drive increased physician awareness and managed care coverage to further grow revenues. In addition, we believe we are well positioned for approval by the U.S. Food and Drug Administration, or FDA, in December to expand Vascepa labeling from our approved MARINE indication to the significantly larger population represented by our proposed ANCHOR indication."

For earnings history and earnings-related data on Amarin Corp Plc (AMRN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities